• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom One CGM sensor launches in France with reimbursement

September 15, 2023 By Sean Whooley

Dexcom One
The Dexcom One platform. [Image from Dexcom]
Dexcom (Nasdaq:DXCM) recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France.

The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.

Dexcom One continuously monitors glucose levels in real-time, sending values wirelessly to a compatible smart device through the app or receiver, which then display trend arrows to show the speed and direction that glucose levels are heading. It also has a range of customizable alerts and access to the Clarity data management software to provide remote data sharing with HCPs. It uses the G6 hardware platform with a different software experience.

The San Diego-based company launched Dexcom One in the UK in April 2022, followed by a pharmacy channel rollout in August 2022. The system already launched in a handful of European countries at the end of 2021. It has availability in Bulgaria, Latvia, Estonia and Lithuania, too.

Launching the CGM platform in France offers patients access to a choice of real-time CGM sensors, the company said.

“We believe this is truly exciting news for people living with diabetes in France,” said Gérald Zammit, country director of Dexcom France. “Access to Dexcom real-time CGM sensors is now available to those who live with diabetes, who aren’t necessarily seen as ‘high risk’, but who can still greatly benefit from it. The launch of Dexcom One in France will help to make real-time CGM accessible to as many patients as possible.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS